This study wants to find out how safe and effective a new medicine, called tirzepatide, is for people with Type 2 Diabetes (T2D) and obesity who are already taking metformin. Metformin is a common medicine for diabetes. The study will last about 89 weeks, which is a little over 1.5 years. You will have a screening period of up to 5 weeks to see if you can join. The main results will be looked at around Week 44, and the study will continue until Week 80. There will be a safety check about 4 weeks after you finish taking the medicine.

• You need to visit the study site multiple times over 89 weeks.
• You must already be using metformin and have a BMI of 35 or more.
• People with Type 1 Diabetes or certain health issues cannot join.

Eligibility: You should have a stable body weight and have been using metformin regularly. Exclusions: If you have Type 1 Diabetes, certain heart conditions, or are using weight loss products, you cannot participate.